OSAAI 2023 Northwest Allergy Forum

Portland, OR US
October 13, 2023 to October 15, 2023

The Oregon Society of Allergy, Asthma & Immunology (OSAAI) 2023 program is an eight-hour event specifically designed to meet perceived unmet needs among practicing allergists, with emphasis on topics that are not covered in other formats.  The OSAAI Faculty are experts in their field and will provide evidence-based, clinical topics that address major aspects of attendee’s practices and will provide attendees exposure to new content. 

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Oregon Society of Allergy, Asthma & Immunology (OSAAI).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 8 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 8 contact hours. 

Target Audience

Practicing allergists
Primary care physicians
Allied healthcare professionals.

Learning Objectives

At the end of this activity, participants should be able to:

1.    Judge an appropriate clinicopathologic endpoint for therapy in EoE
2.    Describe novel targets for management of severe asthma
3.    Apply clinical practice guidelines to the management of patients with chronic urticaria
4.    Discuss key updates in latest drug allergy practice parameter
5.    Explore the role of environmental exposures in pediatric asthma

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
  • 8.00 CBRN
Course opens: 
10/13/2023
Course expires: 
12/31/2024
Event starts: 
10/13/2023 - 5:00pm CDT
Event ends: 
10/15/2023 - 12:30pm CDT
Rating: 
0

OSAAI 2023: Northwest Allergy Forum | October 13-15, 2023
Hyatt Regency | 375 NE Holladay Street | Portland, OR  97232

Friday, October 13th     

5:00pm-7:00pm     Registration, Exhibits & Welcome Reception    

Saturday, October 14th 

7:00am-7:50am    Exhibits | Registration | Coffee Break

7:50am-8:00am    Welcome & Introduction – Shyam Joshi, MD – President, OSAAI
            Session Moderator – Shyam Joshi, MD

8:00am-9:00am     Pediatric Asthma – Jessica Stern, MD, MS            

9:00am-10:00am     Eosinophilic Esophagitis: Clinical Care and Research Updates – Emily Clark McGowan, MD, PhD

10:00am-10:30am    Coffee Break | Exhibits

10:30-11:30am     Updates on Chronic Urticaria – David A. Khan, MD 

11:30am-12:30pm    Updates on Venom Allergy – Karen Anstey, MD

12:30pm    Adjourn

Sunday, October 15th  

7:00am-8:00am    Exhibits | Coffee Break

7:50am-8:00am    Welcome & Introduction
            Session Moderator– Melanie Wayne, OSAAI Board of Directors

8:00am-9:00am        Adult Food Allergy – Emily Clark McGowan, MD, PhD

9:00am-10:00am     Brought to you by the American College of Allergy, Asthma & Immunology: Advocacy Council -
                                Here for You & What’s on Our Horizon – Travis A. Miller, MD, FACAAI 

10:00am-10:30am     Coffee Break | Exhibits 
                       
10:30am-11:30am     Using the 2022 Drug Allergy Parameter Update to Make Your Life Easier – David A. Khan, MD

11:30am-12:30pm     Health Disparities in Allergy and Immunology – Jessica Stern, MD, MS

12:30pm        Adjourn 

Hyatt Regency Portland OR
375 NE Holladay Street
Portland, OR 97232
United States

Disclosure Policy and Disclosures

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 

All identified relevant financial relationships with ineligible companies have been mitigated.

Karen Anstey, MD – Speaker
Stock – 3M

Emily Clarke McGowan, MD, PhD – Speaker
Researcher – Regeneron
Consultant – Regeneron

Shyam Joshi, MD – Planner, Moderator
Advisor – Cogent, Leo Pharma, Sanofi/Regeneron
Advisory Board – Takeda
Researcher – Sanofi/Regeneron

Melanie Wayne, NP – Planner, Moderator
Advisor – CSL Behring

The following have no relevant financial relationships with ineligible companies to disclose:

David A. Khan, MD – Speaker

Travis Miller, MD – Speaker

Jessica Stern, MD, MS – Speaker

James Baker, MD - Planner

Albert Tsien, MD – Planner

Karol Anderson - Planner

Available Credit

  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
  • 8.00 CBRN
Please login or create an account to take this course.